Amporin Pharmaceuticals
Basel, Switzerland· Est. 2018
Amporin Pharmaceuticals is developing a new class of pore-targeting therapies for the treatment of protein misfolding diseases.
Private Company
Total funding raised: $3M
About
Amporin Pharmaceuticals is developing a new class of pore-targeting therapies for the treatment of protein misfolding diseases.
Small Molecules
Funding History
1Total raised:$3M
Seed$3MJun 15, 2020